Regulatory Approval Update

Biocon Pharma Receives USFDA Approval for Dapagliflozin Tablets

NSE

biocon

BSE

532523

Biocon Pharma, a subsidiary of Biocon Limited, has received USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), strengthening its diabetes portfolio and expanding presence in the U.S. generics market.

PRICE-SENSITIVE TRIGGER

Event: USFDA approval for generic drug

Type: Regulatory Approval Update

Impact: Positive

Immediate Effect: Opens new revenue opportunity in diabetes segment

What Happened ?

Biocon Pharma Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Dapagliflozin Tablets (5 mg and 10 mg).

The drug is indicated for the treatment of type 2 diabetes mellitus, helping improve glycemic control and reduce the risk of heart failure hospitalization.

Key details

Product Details

Dapagliflozin Tablets (5 mg & 10 mg)
Used for type 2 diabetes treatment
Helps improve glycemic control and cardiovascular outcomes

Strategic Importance

Strengthens Biocon’s diabetes portfolio
Expands presence in U.S. generics market
Complements existing biosimilars and insulin portfolio

Manufacturing

To be produced at Biocon’s FDA-approved facilities
Meets global regulatory and quality standards

Portfolio Expansion

Supports integrated diabetes care strategy
Enhances product pipeline in chronic therapies

Risk Analysis

Key Risks

Competitive pricing pressure in U.S. generics market
Market share capture challenges
Margin compression

Worst Case Scenario

Limited revenue contribution due to intense competition

Risk Level: Medium

Company Commentary

Expanding global diabetes portfolio
Focus on integrated healthcare solutions
Strengthening presence in regulated markets

Official Exchange Filing: Biocon Pharma Limited